Allison A Eubanks1, Carrie J Nobles2, Sunni L Mumford2, Keewan Kim2, Micah J Hill3, Alan H Decherney3, Lindsey A Sjaarda2, Aijun Ye4, Jeannie G Radoc2, Neil J Perkins2, Robert M Silver5, Enrique F Schisterman2. 1. Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, Maryland. 2. Division of Intramural Population Health Research, Epidemiology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland. 3. Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 4. Glotech, Inc., Rockville, Maryland. 5. Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah.
Abstract
OBJECTIVE: This study aimed to examine whether prenatal low-dose aspirin (LDA) therapy affects risk of cesarean versus vaginal delivery. STUDY DESIGN: This study is a secondary analysis of the randomized clinical effects of aspirin in gestation and reproduction (EAGeR) trial. Women received 81-mg daily aspirin or placebo from preconception to 36 weeks of gestation. Mode of delivery and obstetric complications were abstracted from records. Log-binomial regression models estimated relative risk (RR) of cesarean versus vaginal delivery. Data were analyzed among the total preconception cohort, as well as restricted to women who had a live birth. RESULTS: Among 1,228 women, 597 had a live birth. In the intent-to-treat analysis, preconception-initiated LDA was not associated with risk of cesarean (RR = 1.02; 95% confidence interval [CI]: 0.98-1.07) compared with placebo. Findings were similar in just women with a live birth and when accounting prior cesarean delivery and parity. CONCLUSION: Preconception-initiated daily LDA was not associated with mode of delivery among women with one to two prior losses. KEY POINTS: · Aspirin was not associated with risk of cesarean section.. · Aspirin was not associated with mode of delivery.. · No increased risk of bleeding with use of aspirin.. Thieme. All rights reserved.
OBJECTIVE: This study aimed to examine whether prenatal low-dose aspirin (LDA) therapy affects risk of cesarean versus vaginal delivery. STUDY DESIGN: This study is a secondary analysis of the randomized clinical effects of aspirin in gestation and reproduction (EAGeR) trial. Women received 81-mg daily aspirin or placebo from preconception to 36 weeks of gestation. Mode of delivery and obstetric complications were abstracted from records. Log-binomial regression models estimated relative risk (RR) of cesarean versus vaginal delivery. Data were analyzed among the total preconception cohort, as well as restricted to women who had a live birth. RESULTS: Among 1,228 women, 597 had a live birth. In the intent-to-treat analysis, preconception-initiated LDA was not associated with risk of cesarean (RR = 1.02; 95% confidence interval [CI]: 0.98-1.07) compared with placebo. Findings were similar in just women with a live birth and when accounting prior cesarean delivery and parity. CONCLUSION: Preconception-initiated daily LDA was not associated with mode of delivery among women with one to two prior losses. KEY POINTS: · Aspirin was not associated with risk of cesarean section.. · Aspirin was not associated with mode of delivery.. · No increased risk of bleeding with use of aspirin.. Thieme. All rights reserved.
Authors: Enrique F Schisterman; Robert M Silver; Neil J Perkins; Sunni L Mumford; Brian W Whitcomb; Joseph B Stanford; Laurie L Lesher; David Faraggi; Jean Wactawski-Wende; Richard W Browne; Janet M Townsend; Mark White; Anne M Lynch; Noya Galai Journal: Paediatr Perinat Epidemiol Date: 2013-10-11 Impact factor: 3.980
Authors: Hind N Moussa; Mateo G Leon; Ana Marti; Alissar Chediak; Claudia Pedroza; Sean C Blackwell; Baha M Sibai Journal: Am J Perinatol Date: 2016-09-08 Impact factor: 1.862
Authors: Katherine A Ahrens; Robert M Silver; Sunni L Mumford; Lindsey A Sjaarda; Neil J Perkins; Jean Wactawski-Wende; Noya Galai; Janet M Townsend; Anne M Lynch; Laurie L Lesher; David Faraggi; Shvetha Zarek; Enrique F Schisterman Journal: Obstet Gynecol Date: 2016-04 Impact factor: 7.661
Authors: B M Sibai; S N Caritis; E Thom; M Klebanoff; D McNellis; L Rocco; R H Paul; R Romero; F Witter; M Rosen Journal: N Engl J Med Date: 1993-10-21 Impact factor: 91.245
Authors: Enrique F Schisterman; Robert M Silver; Laurie L Lesher; David Faraggi; Jean Wactawski-Wende; Janet M Townsend; Anne M Lynch; Neil J Perkins; Sunni L Mumford; Noya Galai Journal: Lancet Date: 2014-04-02 Impact factor: 79.321
Authors: Catherine Y Spong; Vincenzo Berghella; Katharine D Wenstrom; Brian M Mercer; George R Saade Journal: Obstet Gynecol Date: 2012-11 Impact factor: 7.661